{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:58:50Z","timestamp":1791464330963,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100007637","name":"COLCIENCIAS","doi-asserted-by":"crossref","award":["Convocatoria 512"],"award-info":[{"award-number":["Convocatoria 512"]}],"id":[{"id":"10.13039\/100007637","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12936-017-1940-7","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T13:22:20Z","timestamp":1500470540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Identification and characterization of the antiplasmodial activity of Hsp90 inhibitors"],"prefix":"10.1186","volume":"16","author":[{"given":"Claribel","family":"Murillo-Solano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia G.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Pizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"1940_CR1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1473-3099(14)70777-7","volume":"14","author":"C Amaratunga","year":"2014","unstructured":"Amaratunga C, Witkowski B, Khim N, Menard D, Fairhurst RM. Artemisinin resistance in Plasmodium falciparum. Lancet Infect Dis. 2014;14:449\u201350.","journal-title":"Lancet Infect Dis"},{"key":"1940_CR2","volume-title":"World malaria report 2014","author":"WHO","year":"2014","unstructured":"WHO. World malaria report 2014. Geneva: World Health Organization; 2014."},{"key":"1940_CR3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm.3077","volume":"19","author":"PL Alonso","year":"2013","unstructured":"Alonso PL, Tanner M. Public health challenges and prospects for malaria control and elimination. Nat Med. 2013;19:150\u20135.","journal-title":"Nat Med"},{"key":"1940_CR4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature15535","volume":"526","author":"S Bhatt","year":"2015","unstructured":"Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207\u201311.","journal-title":"Nature"},{"key":"1940_CR5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/465297a","volume":"465","author":"DA Fidock","year":"2010","unstructured":"Fidock DA. Drug discovery: priming the antimalarial pipeline. Nature. 2010;465:297\u20138.","journal-title":"Nature"},{"key":"1940_CR6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1574-695X.2009.00639.x","volume":"58","author":"A Shonhai","year":"2010","unstructured":"Shonhai A. Plasmodial heat shock proteins: targets for chemotherapy. FEMS Immunol Med Microbiol. 2010;58:61\u201374.","journal-title":"FEMS Immunol Med Microbiol"},{"key":"1940_CR7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1017\/S0033583510000314","volume":"44","author":"KA Krukenberg","year":"2011","unstructured":"Krukenberg KA, Street TO, Lavery LA, Agard DA. Conformational dynamics of the molecular chaperone Hsp90. Q Rev Biophys. 2011;44:229\u201355.","journal-title":"Q Rev Biophys"},{"key":"1940_CR8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature10317","volume":"475","author":"FU Hartl","year":"2011","unstructured":"Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475:324\u201332.","journal-title":"Nature"},{"key":"1940_CR9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrm2918","volume":"11","author":"M Taipale","year":"2010","unstructured":"Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol. 2010;11:515\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1940_CR10","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1093\/emboj\/17.16.4829","volume":"17","author":"B Panaretou","year":"1998","unstructured":"Panaretou B, Prodromou C, Roe SM, O\u2019Brien R, Ladbury JE, Piper PW, et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 1998;17:4829\u201336.","journal-title":"EMBO J"},{"key":"1940_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nsmb.2481","volume":"20","author":"G Chiosis","year":"2013","unstructured":"Chiosis G, Dickey CA, Johnson JL. A global view of Hsp90 functions. Nat Struct Mol Biol. 2013;20:1\u20134.","journal-title":"Nat Struct Mol Biol"},{"key":"1940_CR12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1359-6446(04)03245-3","volume":"9","author":"G Chiosis","year":"2004","unstructured":"Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90: the vulnerable chaperone. Drug Discov Today. 2004;9:881\u20138.","journal-title":"Drug Discov Today"},{"key":"1940_CR13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1017\/S0031182014000778","volume":"141","author":"U Tatu","year":"2014","unstructured":"Tatu U, Neckers L. Chaperoning parasitism: the importance of molecular chaperones in pathogen virulence. Parasitology. 2014;141:1123\u20136.","journal-title":"Parasitology"},{"key":"1940_CR14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1475-2875-11-54","volume":"11","author":"R Mout","year":"2012","unstructured":"Mout R, Xu Z-D, Wolf AKH, Davisson VJ, Jarori GK. Anti-malarial activity of geldanamycin derivatives in mice infected with Plasmodium yoelii. Malar J. 2012;11:54.","journal-title":"Malar J"},{"key":"1940_CR15","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1021\/jm901796s","volume":"53","author":"D Shahinas","year":"2010","unstructured":"Shahinas D, Liang M, Datti A, Pillai DR. A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med Chem. 2010;53:3552\u20137.","journal-title":"J Med Chem"},{"key":"1940_CR16","doi-asserted-by":"crossref","first-page":"37964","DOI":"10.1074\/jbc.M110.155317","volume":"285","author":"R Pallavi","year":"2010","unstructured":"Pallavi R, Roy N, Nageshan RK, Talukdar P, Pavithra SR, Reddy R, et al. Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J Biol Chem. 2010;285:37964\u201375.","journal-title":"J Biol Chem"},{"key":"1940_CR17","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1017\/S0031182014000754","volume":"141","author":"AG Bayih","year":"2014","unstructured":"Bayih AG, Pillai DR. Mouse studies on inhibitors of Plasmodium falciparum Hsp90: progress and challenges. Parasitology. 2014;141:1216\u201322.","journal-title":"Parasitology"},{"key":"1940_CR18","first-page":"742","volume":"1823","author":"K Jhaveri","year":"2012","unstructured":"Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Mol Cell Res. 2012;1823:742\u201355.","journal-title":"Mol Cell Res"},{"key":"1940_CR19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","volume":"18","author":"L Neckers","year":"2012","unstructured":"Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 2012;18:64\u201376.","journal-title":"Clin Cancer Res"},{"key":"1940_CR20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrmicro1835","volume":"6","author":"LE Cowen","year":"2008","unstructured":"Cowen LE. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat Rev Microbiol. 2008;6:187\u201398.","journal-title":"Nat Rev Microbiol"},{"key":"1940_CR21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.mib.2013.03.005","volume":"16","author":"LE Cowen","year":"2013","unstructured":"Cowen LE. The fungal Achilles\u2019 heel: targeting Hsp90 to cripple fungal pathogens. Curr Opin Microbiol. 2013;16:377\u201384.","journal-title":"Curr Opin Microbiol"},{"key":"1940_CR22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1126\/science.1260403","volume":"347","author":"S Mok","year":"2015","unstructured":"Mok S, Ashley EA, Ferreira PE, Zhu L, Lin Z, Yeo T, et al. Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science. 2015;347:431\u20135.","journal-title":"Science"},{"key":"1940_CR23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cbpa.2007.05.038","volume":"11","author":"MH Gelb","year":"2007","unstructured":"Gelb MH. Drug discovery for malaria: a very challenging and timely endeavor. Curr Opin Chem Biol. 2007;11:440\u20135.","journal-title":"Curr Opin Chem Biol"},{"key":"1940_CR24","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.91.18.8324","volume":"91","author":"L Whitesell","year":"1994","unstructured":"Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA. 1994;91:8324\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1940_CR25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002800050817","volume":"42","author":"TW Schulte","year":"1998","unstructured":"Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 1998;42:273\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1940_CR26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00280-001-0380-8","volume":"49","author":"MJ Egorin","year":"2002","unstructured":"Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM, et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol. 2002;49:7\u201319.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1940_CR27","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1021\/jm900230j","volume":"52","author":"KH Huang","year":"2009","unstructured":"Huang KH, Veal JM, Fadden RP, Rice JW, Eaves J, Strachan J-P, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem. 2009;52:4288\u2013305.","journal-title":"J Med Chem"},{"key":"1940_CR28","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1021\/jm100060b","volume":"53","author":"AJ Woodhead","year":"2010","unstructured":"Woodhead AJ, Angove H, Carr MG, Chessari G, Congreve M, Coyle JE, et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem. 2010;53:5956\u201369.","journal-title":"J Med Chem"},{"key":"1940_CR29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/jm701018h","volume":"51","author":"PA Brough","year":"2008","unstructured":"Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, et al. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem. 2008;51:196\u2013218.","journal-title":"J Med Chem"},{"key":"1940_CR30","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.exphem.2008.05.001","volume":"36","author":"T-Y Lin","year":"2008","unstructured":"Lin T-Y, Bear M, Du Z, Foley KP, Ying W, Barsoum J, et al. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol. 2008;36:1266\u201377.","journal-title":"Exp Hematol"},{"key":"1940_CR31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1021\/jm0508078","volume":"49","author":"HZ He","year":"2006","unstructured":"He HZ, Zatorska D, Kim J, Aguirre J, Llauger L, She YH, et al. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J Med Chem. 2006;49:381\u201390.","journal-title":"J Med Chem"},{"key":"1940_CR32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nchembio.1335","volume":"9","author":"PD Patel","year":"2013","unstructured":"Patel PD, Yan P, Seidler PM, Patel HJ, Sun W, Yang C, et al. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat Chem Biol. 2013;9:677\u201384.","journal-title":"Nat Chem Biol"},{"key":"1940_CR33","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1128\/AAC.01313-06","volume":"51","author":"DJ Bacon","year":"2007","unstructured":"Bacon DJ, Latour C, Lucas C, Colina O, Ringwald P, Picot S. Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob Agents Chemother. 2007;51:1172\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1940_CR34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cmpb.2010.08.003","volume":"104","author":"H Nagard Le","year":"2011","unstructured":"Le Nagard H, Vincent C, Mentr\u00e9 F, Le Bras J. Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Comput Methods Programs Biomed. 2011;104:10\u20138.","journal-title":"Comput Methods Programs Biomed"},{"key":"1940_CR35","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1086\/656476","volume":"202","author":"F Teuscher","year":"2010","unstructured":"Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J Infect Dis. 2010;202:1362\u20138.","journal-title":"J Infect Dis"},{"key":"1940_CR36","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1002\/prot.22799","volume":"78","author":"KD Corbett","year":"2010","unstructured":"Corbett KD, Berger JM. Structure of the ATP-binding domain of Plasmodium falciparum Hsp90. Proteins. 2010;78:2738\u201344.","journal-title":"Proteins"},{"key":"1940_CR37","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785\u201391.","journal-title":"J Comput Chem"},{"key":"1940_CR38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455\u201361.","journal-title":"J Comput Chem"},{"key":"1940_CR39","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1093\/jac\/dkv199","volume":"70","author":"A Hott","year":"2015","unstructured":"Hott A, Tucker MS, Casandra D, Sparks K, Kyle DE. Fitness of artemisinin-resistant Plasmodium falciparum in vitro. J Antimicrob Chemother. 2015;70:2787\u201396.","journal-title":"J Antimicrob Chemother"},{"key":"1940_CR40","doi-asserted-by":"crossref","first-page":"205ra135","DOI":"10.1126\/scitranslmed.3006684","volume":"5","author":"RP Bakshi","year":"2013","unstructured":"Bakshi RP, Nenortas E, Tripathi AK, Sullivan DJ, Shapiro TA. Model system to define pharmacokinetic requirements for antimalarial drug efficacy. Sci Transl Med. 2013;5:205ra135.","journal-title":"Sci Transl Med"},{"key":"1940_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-12-424","volume":"12","author":"C Manach Le","year":"2013","unstructured":"Le Manach C, Scheurer C, Sax S, Schleiferb\u00f6ck S, Cabrera DG, Younis Y, et al. Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum. Malar J. 2013;12:1.","journal-title":"Malar J"},{"key":"1940_CR42","doi-asserted-by":"crossref","first-page":"35612","DOI":"10.1074\/jbc.M704647200","volume":"282","author":"S Frey","year":"2007","unstructured":"Frey S, Leskovar A, Reinstein J, Buchner J. The ATPase cycle of the endoplasmic chaperone Grp94. J Biol Chem. 2007;282:35612\u201320.","journal-title":"J Biol Chem"},{"key":"1940_CR43","doi-asserted-by":"crossref","first-page":"e75446","DOI":"10.1371\/journal.pone.0075446","volume":"8","author":"D Shahinas","year":"2013","unstructured":"Shahinas D, Folefoc A, Taldone T, Chiosis G, Crandall IE, Pillai DR. A purine analog synergizes with chloroquine (CQ) by targeting Plasmodium falciparum Hsp90 (PfHsp90). PLoS ONE. 2013;8:e75446.","journal-title":"PLoS ONE"},{"key":"1940_CR44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ctrv.2012.10.001","volume":"39","author":"DS Hong","year":"2013","unstructured":"Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev. 2013;39:375\u201387.","journal-title":"Cancer Treat Rev"},{"key":"1940_CR45","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673\u201383.","journal-title":"Nat Rev Drug Discov"},{"key":"1940_CR46","doi-asserted-by":"crossref","first-page":"e2699","DOI":"10.1371\/journal.pntd.0002699","volume":"8","author":"V Gillan","year":"2014","unstructured":"Gillan V, O\u2019Neill K, Maitland K, Sverdrup FM, Devaney E. A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes. PLoS Negl Trop Dis. 2014;8:e2699.","journal-title":"PLoS Negl Trop Dis"},{"key":"1940_CR47","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1128\/AAC.00328-12","volume":"56","author":"D Shahinas","year":"2012","unstructured":"Shahinas D, Macmullin G, Benedict C, Crandall IE, Pillai DR. Harmine is a potent antimalarial targeting Hsp90 and synergizes with chloroquine and artemisinin. Antimicrob Agents Chemother. 2012;56:4207\u201313.","journal-title":"Antimicrob Agents Chemother"},{"key":"1940_CR48","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/1475-2875-9-236","volume":"9","author":"R Pallavi","year":"2010","unstructured":"Pallavi R, Acharya P, Chandran S, Daily JP, Tatu U. Chaperone expression profiles correlate with distinct physiological states of Plasmodium falciparum in malaria patients. Malar J. 2010;9:236.","journal-title":"Malar J"},{"key":"1940_CR49","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1021\/jm400619b","volume":"56","author":"T Taldone","year":"2013","unstructured":"Taldone T, Patel PD, Patel M, Patel HJ, Evans CE, Rodina A, et al. Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series. J Med Chem. 2013;56:6803\u201318.","journal-title":"J Med Chem"},{"key":"1940_CR50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bmcl.2013.11.036","volume":"24","author":"JT Ernst","year":"2014","unstructured":"Ernst JT, Liu M, Zuccola H, Neubert T, Beaumont K, Turnbull A, et al. Correlation between chemotype-dependent binding conformations of HSP90\u03b1\/\u03b2 and isoform selectivity\u2014implications for the structure-based design of HSP90\u03b1\/\u03b2 selective inhibitors for treating neurodegenerative diseases. Bioorg Med Chem Lett. 2014;24:204\u20138.","journal-title":"Bioorg Med Chem Lett"},{"key":"1940_CR51","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1021\/acs.biochem.5b00148","volume":"54","author":"BE Nordin","year":"2015","unstructured":"Nordin BE, Liu Y, Aban A, Brown HE, Wu J, Hainley AK, et al. ATP acyl phosphate reactivity reveals native conformations of Hsp90 paralogs and inhibitor target engagement. Biochemistry. 2015;54:3024\u201336.","journal-title":"Biochemistry"},{"key":"1940_CR52","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/infdis\/jit179","volume":"208","author":"KJ Meyer","year":"2013","unstructured":"Meyer KJ, Shapiro TA. Potent anti-trypanosomal activities of Hsp90 inhibitors in vitro and in vivo. J Infect Dis. 2013;208:489\u201399.","journal-title":"J Infect Dis"},{"key":"1940_CR53","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.4161\/cc.3.12.1277","volume":"3","author":"F Burrows","year":"2004","unstructured":"Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle. 2004;3:1530\u20136.","journal-title":"Cell Cycle"},{"key":"1940_CR54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pt.2014.01.004","volume":"30","author":"PD Roepe","year":"2014","unstructured":"Roepe PD. To kill or not to kill, that is the question: cytocidal antimalarial drug resistance. Trend Parasitol. 2014;30:130\u20135.","journal-title":"Trend Parasitol"},{"key":"1940_CR55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1475-2875-12-187","volume":"12","author":"JN Burrows","year":"2013","unstructured":"Burrows JN, van Huijsduijnen RH, M\u00f6hrle JJ, Oeuvray C, Wells TNC. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013;12:187.","journal-title":"Malar J"},{"key":"1940_CR56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1475-2875-2-30","volume":"2","author":"R Kumar","year":"2003","unstructured":"Kumar R, Musiyenko A, Barik S. The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin. Malar J. 2003;2:30.","journal-title":"Malar J"},{"key":"1940_CR57","doi-asserted-by":"crossref","first-page":"13891","DOI":"10.1038\/srep13891","volume":"5","author":"BT Mott","year":"2015","unstructured":"Mott BT, Eastman RT, Guha R, Sherlach KS, Siriwardana A, Shinn P, et al. High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. Sci Rep. 2015;5:13891.","journal-title":"Sci Rep"},{"key":"1940_CR58","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2165\/00003495-199652060-00004","volume":"52","author":"PJ Vries de","year":"1996","unstructured":"de Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs. 1996;52:818\u201336.","journal-title":"Drugs"},{"key":"1940_CR59","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1021\/jm401801t","volume":"57","author":"T Wang","year":"2014","unstructured":"Wang T, Bisson WH, M\u00e4ser P, Scapozza L, Picard D. Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 orthologues enable the structure-based discovery of pathogen-selective inhibitors. J Med Chem. 2014;57:2524\u201335.","journal-title":"J Med Chem"},{"key":"1940_CR60","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1021\/acs.jmedchem.6b00591","volume":"59","author":"T Wang","year":"2016","unstructured":"Wang T, M\u00e4ser P, Picard D. Inhibition of Plasmodium falciparum Hsp90 contributes to the antimalarial activities of aminoalcohol-carbazoles. J Med Chem. 2016;59:6344\u201352.","journal-title":"J Med Chem"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-017-1940-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T16:42:55Z","timestamp":1719333775000},"score":1,"resource":{"primary":{"URL":"http:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-017-1940-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1940"],"URL":"https:\/\/doi.org\/10.1186\/s12936-017-1940-7","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]},"article-number":"292"}}